FindTrial
Sign In

Tests to prove the efficacy and safety of the Hycos Membraderm gel product in humans suffering from acute or chronic wounds in infected or non-infected lesions

Single-blind study of efficacy and safety of the Hycos Membraderm gel product in humans

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-478xd66
Enrollment
Unknown
Registered
2025-05-22
Start date
2025-04-30
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pressure Ulcer

Interventions

To prove the efficacy and safety of the Hycos Membraderm gel product in humans affected by acute or chronic wounds in infected or uninfected lesions and demonstrate the action of the product in a fast
E04.987

Sponsors

Nipo Serviços Médicos SS Ltda
Lead Sponsor
Nipo Serviços Médicos SS Ltda
Collaborator

Eligibility

Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients who are in the initial phase of treatment and have skin lesions resulting from wounds, cuts, bedsores and ulcers. Patients who have never undergone treatment and those who are already taking medication. Age between 18 and 90 years. Any ethnicity, color/race, phototype, and of both sexes

Exclusion criteria

Exclusion criteria: Pregnancy. Patients under 18 years of age. Sensitivity to product components

Design outcomes

Primary

MeasureTime frame
To demonstrate the efficacy and safety of Hycos Membraderm Gel in humans affected by acute or chronic wounds in infected or non-infected lesions—

Secondary

MeasureTime frame
No secondary outcomes are expected—

Countries

Brazil

Contacts

Public ContactFrederico Viana

TCI Laboratório Biotecnológico Ltda

frederico@tcilab.com.br+55 38 99886-3565

Outcome results

None listed

Source: REBEC (via WHO ICTRP)